Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.

Patients whose tumors were PD-L1 positive and sTIL-high (≥30%) had a numerically higher pCR rate of 57% than those with PD-L1 positive but sTIL intermediate or low cancers (pCR rate 50%) or PD-L1 negative cancers (pCR rate 32%), but these differences did not reach statistical significance ( p = 0.302, two-sided Fisher’s exact test).

also in 111,027 other papers